Home / About / Governance / Commercialization & Legacy Committee

Commercialization Committee

The Commercialization & Legacy Committee helps identify projects with translational potential, engages partners, guides intellectual property (IP) protection, and directs commercialization strategies, in addition to developing and implementing GlycoNet’s legacy plan.

Members of the Committee

Dr. Wilson is currently the Director of Business Development at Quark Venture, a Vancouver based venture capital group that invests globally in health science. Investing out of the $500M USD Global Health Sciences Fund, Dr. Wilson works closing with Quark’s Executive Team to identify and diligence potential investment opportunities.

Samuel currently serves as a Strategic Advisor to Western Economic Diversification, and as a board member to Inspire Health, the Institute for Health Systems Transformation and Sustainability, and the Vancouver Prostate Centre, as well as a member of the Scientific Advisory Board of Quest Pharma and as a Key Opinion Leader for Quark Venture Inc.

Christine is a science executive with over 25 years of investment, advisory, business development and marketing experience. She is an expert in translating scientific data into market potential and concrete company strategy. Most recently Managing Partner and Founder of Scientia Advisors and Investments where she advised and facilitated fundraising for emerging life sciences companies, Christine has extensive experience in capital markets, strategic planning and analysis.

Christopher’s practice focuses on mergers and acquisitions and finance transactions, as well as advising on governance and general corporate and securities law matters. His clients include private equity and venture capital funds and companies ranging from publicly traded multinationals to early-stage ventures manufacturing.

Stephanie is an accomplished patent professional with a proven track record of building and maximizing the value of her clients’ intellectual property assets. Stephanie has over 17 years of experience in patent portfolio development and IP counseling, where she is skilled in integrating IP strategy with business strategy. Stephanie’s practice concentrates on the protection of chemical and biochemical technologies in various industry sectors, including cleantech, chemical manufacturing, pharmaceutical, medical device, life sciences, oil & gas and alternative energy.

Dr. Borovina is a Managing Director on the investment banking team at Bloom Burton where she leads the firm’s scientific ideation team and management consulting practice, providing clients with advice on scientific, clinical and capital markets strategy. Dr. Borovina has been with Bloom Burton since 2014 and has held several positions in the firm, most recently as an analyst on the equity research team, where she researched publicly traded healthcare companies and made investment recommendations. Prior to joining Bloom Burton, she gained business development experience while working for GeneYouIn, a direct-to-consumer genetic testing startup. Dr. Borovina currently serves on the Emerging Companies Advisory Board of BIOTECanada, the national biotechnology industry association.

Dr. Ghanei brings over 10 years of experience in business development and venture formation. He has a successful track record of managing and leading transactions with licensing and mergers and acquisitions deals worth over $1.5 billion. He has generated over 500 new business leads, resulting in portfolio expansions and increasing revenue potential by 800%. Dr. Ghanei has a deep knowledge of the various aspects of the pharmaceutical industry, and he excels in building partnerships and leading cross-functional teams in complex projects.


Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.

Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.

Terms of Reference

View Terms of Reference (PDF)

Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147

Subscribe to GlycoNet’s Newsletter


Scroll to Top